Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 




ALSP Inc. is led by a dedicated team of experienced executives, scientists and thought leaders that have extensive business and clinical experience in drug development.


-
...TBI increases risk of dementia by as much as two-fold
  

ALSP Inc. Management Team

 

Michael D. Pierschbacher, Ph.D.

President and Chief Executive Officer

Steven Jacobsen, Ph.D. 

Sr. Vice President and Chief Scientific Officer


Gregory Hook, Ph.D., J.D.

Co-Founder, Vice President Research, and Corporate Counsel


Robert J. Ternansky, Ph.D.
Vice President, Medicinal Chemistry 

 

Gregory P. Einhorn, Ph.D., J.D.

Vice President, Intellectual Property


< Back

 

Robert J. Ternansky, Ph.D.

Vice President, Medicinal Chemistry


Dr. Ternansky brings to ALSP Inc. extensive experience in medicinal chemistry, especially in the design and development of small molecule protease inhibitors. He currently also serves as Lecturer at the University of California, San Diego.

 

Dr. Ternansky was previously the Senior Vice President of Chemistry at Attenuon, LLC where he led the chemistry efforts that resulted in the advancement of two compounds through Phase II clinical trials in cancer.

 

Prior to Attenuon, Dr. Ternansky served as Director of Medicinal Chemistry at IDUN Pharmaceuticals, Inc. in San Diego where he co-invented a lead series of caspase inhibitors for the prevention of apoptotic cell death; held the position of Associate Director of Inflammation at La Jolla Pharmaceuticals, Inc., where he led the analytical team on the pre-clinical development of LJP-394, a toleragen for the treatment of lupus; was a Research Scientist and Team Leader at Eli Lilly and Co., where he invented LY193239, the first pyrazolidinone antibacterial agent to be developed for clinical investigation. He was also a member of the pre-clinical discovery/development team for loracarbef (Lorabid), the first marketed 1-carbacephalosporin antibacterial agent. Finally, Dr. Ternansky is also a co-inventor of trovirdine, a NNRT inhibitor of HIV-1 RT, which progressed through Phase II trials for the treatment of HIV infection.

 

Dr. Ternansky received his Ph.D. in Synthetic Organic Chemistry from The Ohio State University.